Abstract

The purpose — to give clinical and metabolic characteristics of patients with type 2 diabetes who survived and died from COVID-19. Material and methods. The object of observation: patients (159 patients aged 40 to 90 years old) hospitalized in a repurposed infectious diseases hospital for the treating patients with COVID-19. Two groups were distinguished: patients with type 2 diabetes mellitus who survived (group 1a) and died from COVID-19. The design of the work involved a comparative assessment of the initial clinical and metabolic parameters in patients of both groups. Results. There were no statistically significant differences in age, BMI, duration of the outpatient phase, cholesterol, troponin, APTT, PTT, fibrinogen between the study groups. Patients with type 2 diabetes who died from COVID-19 showed a higher level of glycemia, a three times higher area of lung damage, reduced saturation, a more pronounced inflammatory reaction, manifested as an increase in serum ferritin (2.7 times), C-reactive protein — 1.5 times and immune suppression. The level of D—dimer was 2.7 times higher, the aaactivity of liver enzymes was 1.5 times higher, the number of lymphocytes was reduced 2 times. Conclusion. A high level of mortality under the maximum fulfillment of the requirements for the quality of diagnosis and treatment indicates the comorbidity severity and the need to refine the treatment tactics of this category of patients.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.